vs
Side-by-side financial comparison of Edwards Lifesciences (EW) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.3B vs $1.6B, roughly 1.4× Edwards Lifesciences). Zoetis runs the higher net margin — 26.6% vs 23.1%, a 3.5% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs 2.9%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs -2.1%).
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
EW vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.6B | $2.3B |
| Net Profit | $380.7M | $601.0M |
| Gross Margin | 78.0% | 71.7% |
| Operating Margin | 1.8% | — |
| Net Margin | 23.1% | 26.6% |
| Revenue YoY | 16.7% | 2.9% |
| Net Profit YoY | 6.8% | -0.2% |
| EPS (diluted) | $0.66 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.6B | $2.3B | ||
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.6B | $2.4B | ||
| Q2 25 | $1.5B | $2.5B | ||
| Q1 25 | $1.4B | $2.2B | ||
| Q4 24 | $1.4B | $2.3B | ||
| Q3 24 | $1.4B | $2.4B | ||
| Q2 24 | $1.4B | $2.4B |
| Q1 26 | $380.7M | $601.0M | ||
| Q4 25 | $91.2M | $603.0M | ||
| Q3 25 | $291.1M | $721.0M | ||
| Q2 25 | $333.2M | $718.0M | ||
| Q1 25 | $358.0M | $631.0M | ||
| Q4 24 | $385.6M | $581.0M | ||
| Q3 24 | $3.1B | $682.0M | ||
| Q2 24 | $366.3M | $624.0M |
| Q1 26 | 78.0% | 71.7% | ||
| Q4 25 | 78.1% | 70.2% | ||
| Q3 25 | 77.8% | 71.5% | ||
| Q2 25 | 77.5% | 73.6% | ||
| Q1 25 | 78.7% | 72.0% | ||
| Q4 24 | 78.9% | 69.5% | ||
| Q3 24 | 80.6% | 70.6% | ||
| Q2 24 | 79.9% | 71.7% |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 9.6% | 31.9% | ||
| Q3 25 | 19.8% | 37.0% | ||
| Q2 25 | 26.8% | 36.7% | ||
| Q1 25 | 27.9% | 36.5% | ||
| Q4 24 | 22.6% | 31.6% | ||
| Q3 24 | 25.9% | 36.6% | ||
| Q2 24 | 26.8% | 33.0% |
| Q1 26 | 23.1% | 26.6% | ||
| Q4 25 | 5.8% | 25.3% | ||
| Q3 25 | 18.7% | 30.0% | ||
| Q2 25 | 21.7% | 29.2% | ||
| Q1 25 | 25.3% | 28.4% | ||
| Q4 24 | 27.8% | 25.1% | ||
| Q3 24 | 226.7% | 28.6% | ||
| Q2 24 | 26.7% | 26.4% |
| Q1 26 | $0.66 | $1.42 | ||
| Q4 25 | $0.16 | $1.37 | ||
| Q3 25 | $0.50 | $1.63 | ||
| Q2 25 | $0.56 | $1.61 | ||
| Q1 25 | $0.61 | $1.41 | ||
| Q4 24 | $0.65 | $1.29 | ||
| Q3 24 | $5.13 | $1.50 | ||
| Q2 24 | $0.61 | $1.37 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EW
Segment breakdown not available.
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
